Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- THE ROSEN LAW FIRM, P. A.SPRY Deadline: SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud LawsuitWhy: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) between March 9, 2026 and June 24, 2026, inclusive (the "Class Period"), of the important October 5, 2026 lead...
- THE ROSEN LAW FIRM, P. A.UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud LawsuitWhy: New York, N.Y., September 28, 2026. Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between December 29, 2025 and June 29, 2026, both dates inclusive (the...
- Evosep and Mass Dynamics Join Forces to Standardize Proteomics Sample Preparation for PharmaEvosep and Mass Dynamics partner to standardize proteomics workflows, combining automated sample prep, QC, and analytics for pharma.
- ARS PHARMACEUTICALS DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 5 Deadline in Securities Class Action – SPRYWHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) between March 9, 2026 and June 24, 2026, inclusive (the “Class Period”), of the important October 5, 2026 lead plaintiff deadline.
- Fuse Oncology, Inc.Fuse Oncology and Associated Medical Professionals of NY Launch Proof of Concept for End-to-End Radiation Oncology Workflow in UrologySyracuse practice, part of U.S. Urology Partners, a General Atlantic company, will run a first proof of concept of FuseRx, with ACRO clinical pathways built in, at its radiation oncology program in Syracuse SYRACUSE, N.Y. and BOONE, N.C., Sept. 28, 2026 -- Fuse Oncology and...
- Belite Bio, IncBelite Bio Announces Oral Presentations at Two Upcoming Medical ConferencesBelite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that its data will be presented at the Euretina Innovation Spotlight (EIS) being held on September 30, 2026, and Euretina being held on October 1-4, 2026, in Vienna, Austria.
- ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCYWHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between December 29, 2025 and June 29, 2026, both dates inclusive (the “Class Period”), of the important November 2, 2026 lead plaintiff deadline.
- Truth InitiativeFDA Must Maintain Strong Scientific Review Process for New Tobacco Products and Crack Down on Illegal Marketplace to Protect Public HealthStatement from Kathy Crosby, CEO and President of Truth Initiative — Today, the U.S. Food and Drug Administration announced that it plans to evaluate changes to the framework for applications for new tobacco products like e-cigarettes and nicotine...
- GenentechGenentech Breaks Ground on $750 Million Manufacturing Expansion in Hillsboro, OregonSOUTH SAN FRANCISCO, Calif., September 28, 2026--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), today broke ground on a $750 million expansion of its manufacturing facility in Hillsboro, Oregon, advancing plans announced in August to increase capacity for advanced drug delivery devices and to strengthen the company’s United States manufacturing capabilities. The event marks the start of construction for the 211,000-square-feet expansion, doubling the size of the existing si
- Egetis Therapeutics Announces U.S. FDA Approval of EMCITATE® (tiratricol) for Patients with MCT8 DeficiencySTOCKHOLM, SWEDEN, Sept. 28 2026. – Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (Nasdaq Stockholm: EGTX) today announced that the U.S. Food and Drug Administration (FDA) has approved EMCITATE® (tiratricol), a thyroid hormone receptor agonist, for the treatment of peripheral thyrotoxicosis in adults and pediatric patients with monocarboxylate transporter 8 (MCT8) deficiency (Allan–Herndon–Dudley syndrome). EMCITATE is not recommended for the treatment of primary hypothyroidism. EMCITATE is the first FDA-approved treatment option for patients with MCT8 deficiency in the United States.
- Summit Therapeutics Inc.AstraZeneca Makes $2 Billion Strategic Equity Investment in Summit TherapeuticsCompanies: AstraZenecaMIAMI, September 28, 2026--Summit Therapeutics Inc. (Nasdaq: SMMT) today announced key developments important to the company’s progress towards achieving its goal of making a significant difference in the lives of patients with cancer. Specifically, Summit has established agreements with AstraZeneca (LSE/STO/NYSE: AZN) for a strategic equity investment in Summit and a clinical collaboration focused on ivonescimab and sonesitatug vedotin (sone-ve).
- Citizens Commission on Human Rights International Los AngelesCoroner Finds Multiple Psychiatric Drugs in Mother-Daughter Murder-Suicide; Citizens Commission on Human Rights International Calls for Violence Cases to Undergo Same TestsGroup cites 12 deaths in five 2026 attacks and urges states to require psychiatric-drug toxicology in homicides and mass acts of senseless violence